乙胺对健康成年人的肺血液动力学和右心功能的影响:随机对照试验
Laura Mayer1, Mona Lichtblau1,2, Michael Furian1
1Department of Pulmonology University Hospital Zurich Switzerland.
Journal of the American Heart Association
|August 29, 2025
概括
在健康成年人中,预防性乙胺并没有显著降低高空肺动脉压力. 在改善氧和的同时,它改变了血液动力学,可能减少整体氧气供应.
科学领域:
- 心脏病学
- 高空医学
- 药理学
背景情况:
- 高空暴露会导致低氧肺血管收缩,增加肺动脉压力 (PAP).
- 这可能导致肺高血压,右心功能受损,运动能力下降.
- 预防性乙胺可以减轻这些高度诱导的影响.
研究的目的:
- 调查乙胺是否可以防止高海拔引起的PAP增加.
- 在3100米处评估乙胺对血液动力学和右心功能的影响.
- 评估乙胺在未经适应的中年低地居民中的疗效.
主要方法:
- 一个安慰剂对照的双盲试验,涉及生活在800米以下的健康成年人 (> 40岁).
- 在登上3100米之前的24小时,参与者接受了乙胺 (375mg/天) 或安慰剂.
- 在760米处进行心声扫描,在第一天晚上后在3100米处进行心声扫描,以测量静脉动脉率,血液动力学和右心功能替代物.
主要成果:
- 与安慰剂相比,阿西塔佐拉米德治疗的趋势是降低静脉血压 (-2. 5 mmHg,P=0. 087).
- 脉冲氧测和率 (+2%),心率 (-5/ 分) 和心力输出量 (- 0. 8 L/ 分) 均显著改善.
- 然而,氧气输送减少了 (-123毫升/分钟),部分面积变化减少了 (-4%).
结论:
- 在健康的中年成年人中,预防性乙胺并没有显著减轻高度诱导的PAP增加.
- 药物改变了血液动力学和右心功能,可能通过减少氧气输送来抵消益处.
- 需要进一步的研究来了解适应和氧气运输的净效应.
更多相关视频
07:38Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
3.9K
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
16.9K
相关概念视频
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23